Navigation Links
Bioheart, Inc. and Global Stem Cells, Inc. Announce New Clinical Site in Mexico
Date:11/30/2013

lized at the center in Cozumel, offering treatments to patients for a variety of different indications.

About Bioheart, Inc.:

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart’s goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit http://www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

About the Global Stem Cell Group

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Group’
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ACRES Names Katherine Madigan VP for Global Alliances and Advocacy
2. Scar Global Clinical Trials Review, H2, 2013
3. Acute Pain Global Clinical Trials Review, H2, 2013
4. Barretts Esophagus Global Clinical Trials Review, H2, 2013
5. ITRA Global Report Makes the Case That Bio Tech Companies Should Consider Tucson, Arizona for Relocation or Expansion
6. Advancements in High-Speed DNA Synthesis to Drive Growth in the Global Synthetic Biology Market, According to New Report by Global Industry Analysts, Inc.
7. Grace Century, FZ LLC Publishes Annual Global and Regional Financial Predications for 2014
8. Molecular Diagnostics - Global Strategic Business Report
9. Everest Group Recognizes TCS as a Global Leader and Star Performer in Life Sciences IT Outsourcing
10. ISPE Announces Recipients of 2013 International Honor Awards at Global Annual Meeting
11. Prefilled Syringes Market Expected to Reach USD 4.98 Billion Globally in 2019: Transparency Market Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Through rare discovery of new physics ... is enabling World Scientists to actually see, watch, ... displaying the full nature (position, shape, size, number) of ... Porter, Co-Founder of the Yancy Corporation, says, "Our rare ... They come once in a lifetime, if at all. ...
(Date:6/1/2015)... Chosen for his engaging style ... has been selected as keynote speaker for a ... will deliver his keynote: "Don't Stop Thinking About ... to the American Medical Association, Blue Cross Blue ... Forum on Wireless Healthcare, United Healthcare, IASIS Healthcare, ...
(Date:6/1/2015)... and RARITAN, N.J. ... Development, LLC (Janssen) announced data from the Phase ... improvement in progression-free survival (PFS) with trabectedin (YONDELIS ... advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated ... chemotherapy regimen. SAR3007 is the largest randomized Phase ...
(Date:6/1/2015)... , June 1, 2015  Novartis is highlighting ... of CTL019, an investigational chimeric antigen receptor (CAR) ... the treatment of specific types of hard-to-treat non-Hodgkin ... the University of Pennsylvania,s Perelman School of Medicine ... diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma ...
Breaking Biology Technology:Scientists Eying Rare Discovery Of New Physics & Light Microscope Technology 2Futurist Jack Uldrich to Address the Future of Pharmaceuticals 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6
... CRANBURY, N.J., Aug. 12 Palatin Technologies, Inc. (NYSE ... of a Phase 1 clinical trial of subcutaneously administered ... male erectile dysfunction (ED) and female sexual dysfunction (FSD). ... blood plasma levels can be obtained without blood pressure ...
... Health care jobs continue ... industry remains at 20,000 monthly, and health care has one of the the lowest unemployment rates ... feeling the economic pinch more and more. , ... (Vocus) August 12, 2009 -- There is a dichotomy between simultaneous job creation and job ...
... Scientists drew fittingly from Roman mythology when they named ... Janus, who is usually depicted as having two faces ... been fascinated by the tantalizing possibilities of these particles ... and many other devices. However, realizing these applications requires ...
Cached Biology Technology:Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration 2Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration 3Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration 4The MedZilla Report for July, 2009 - Health Care Creates 20,000 More Jobs As Economy Hits Insurers 2The MedZilla Report for July, 2009 - Health Care Creates 20,000 More Jobs As Economy Hits Insurers 3The MedZilla Report for July, 2009 - Health Care Creates 20,000 More Jobs As Economy Hits Insurers 4Capping a two-faced particle gives duke engineers complete control 2
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, reminds investors and media that  Mr. ...  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of nine ... Global Fraud: Where is the Trust in Cyberspace? ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... Through the generous support of the Breast ... Cancer Research (AACR) is pleased to announce the ... Translational Breast Cancer Research. These grants provide ... designed to accelerate the discovery, development, and application ...
... DC Some nanotechnology fanciers suggest that, like ... will flock or clump together. ... risks as nanotechnology manufacturing increases and the number ... nanoparticle expert Andrew Maynard, chief science advisor to ...
... A modified plastic material greatly improves the ability to ... the gas is prepared for use, according to engineers ... analyzed the new plastics performance. Like a sponge ... permits carbon dioxide or other small molecules to go ...
Cached Biology News:AACR, BCRF award inaugural grants in translational breast cancer research 2AACR, BCRF award inaugural grants in translational breast cancer research 3Nanoparticle exposures happen, says expert 2New membrane strips carbon dioxide from natural gas faster and better 2New membrane strips carbon dioxide from natural gas faster and better 3
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
Phosphorylcholine hapten is conjugated to BSA protein by use of p-diazonium phenylphosphorylcholine....
Viral CMV UL146/vCXC1 Biotinylated Affinity Purified PAb...
Blue Standard is 3-cyano-7-hydroxycoumarin....
Biology Products: